IGI, INC. IG announced that Boston University has applied for a patent for an invention using IGI Inc's patented Novasome(R) lipid microvesicles. The invention relates to a new method for the improved localized delivery of H2 antagonists for the treatment and/or prevention of periodontal disease. The described method involves topical administration of a H2 antagonist encapsulated with the Novasome(R) microvesicle delivery system. The Novasome(R)-based system is thought to lead to increased local absorption of the H2 antagonist and enhanced drug action. In an experimental study, the inventors have shown that topical administration of a preparation of the H2 antagonist, cimetidine, in Novasome(R) microvesicles prevented gingival inflammation and bone destruction in a rabbit periodontitis model. According to the inventors, Novasome(R) delivery of H2 antagonists could find applications in the management of inflammatory skin and other disorders.
"We continue to find new applications for our Novasome(R) nano-vesicular delivery technology for use in the marketplace. Periodontal disease ("PD") is a common ailment and affects a significant portion of American adults. PD is a major cause of tooth loss, and has been implicated in a number of serious human health problems including premature delivery, coronary artery disease, gastrointestinal disorders, neurologic diseases, and others. This broadens our platform technology into new areas for the treatment and prevention of skin and periodontal disorders." stated Frank Gerardi, Chairman and CEO of IGI, Inc.
IGI is a company committed to growth by applying its proprietary technologies to achieve cost-effective solutions with differential consumer advantages for its customers. IGI's patented Novasome(R) nano-vesicular delivery technology offers value-added qualities to cosmetics, skin care products, dermatological formulations and other consumer products, providing improved dermal absorption, controlled and sustained release as well as improved stability and greater ease of formulation. IGI has licensed Novasome(R) nano-vesicular delivery technology to leading global dermatological and skin care companies including Johnson & Johnson Consumer Products, Inc., Estee Lauder Corporation, Genesis Pharmaceutical, Inc. and Apollo Pharmaceutical, Inc., and recently sub-licensed the rights to obtain FDA approval for and market IGI's PTH (1-34) compound using Novasome(R) nano-vesicular delivery technology for psoriasis, which is slated for Phase II clinical trials, to Tarpan Pharmaceuticals, Inc. IGI is also exploring the licensing of the topical PTH (7-34) compound for the prevention/treatment of chemotherapy induced-alopecia in patients undergoing chemotherapy.
The statements in this release are forward-looking statements that are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including the following: changes in demand for the Company's products, product mix, the timing of customer orders or deliveries, the impact of competitive products and pricing, constraints on supplies of critical components, excess or shortage of production capacity and other risks discussed from time to time in the Company's SEC filings. In addition, such statements could be affected by general industry and market conditions and growth rates, and general domestic and international economic conditions. Such forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the release.
Contact Information: IGI, Inc. Frank Gerardi, 856-697-1441 ext. 102 www.askigi.com
© 2005 BusinessWire